Early Rash Development May Signal Superior Benefit With Lapatinib

Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.

Frontiers Cutaneous manifestations associated with immune checkpoint inhibitors

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Frontiers Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer - ScienceDirect

Lapatinib

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer - ScienceDirect

Frontiers Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Figure 1 from Lapatinib for advanced or metastatic breast cancer.

Full article: Lapatinib: new opportunities for management of breast cancer

Early Adverse Events predict Survival Outcomes in HER2-positive

10-K

Dermatologic Adverse Events